LT3426243T - 3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas - Google Patents

3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas

Info

Publication number
LT3426243T
LT3426243T LTEP17764026.5T LT17764026T LT3426243T LT 3426243 T LT3426243 T LT 3426243T LT 17764026 T LT17764026 T LT 17764026T LT 3426243 T LT3426243 T LT 3426243T
Authority
LT
Lithuania
Prior art keywords
dehydrogenase inhibitors
phosphoglycerate dehydrogenase
phosphoglycerate
inhibitors
dehydrogenase
Prior art date
Application number
LTEP17764026.5T
Other languages
English (en)
Inventor
Nello Mainolfi
Original Assignee
Raze Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raze Therapeutics, Inc. filed Critical Raze Therapeutics, Inc.
Publication of LT3426243T publication Critical patent/LT3426243T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
LTEP17764026.5T 2016-03-09 2017-03-08 3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas LT3426243T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305930P 2016-03-09 2016-03-09
PCT/US2017/021420 WO2017156165A1 (en) 2016-03-09 2017-03-08 3-phosphoglycerate dehydrogenase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
LT3426243T true LT3426243T (lt) 2021-08-10

Family

ID=59789738

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17764026.5T LT3426243T (lt) 2016-03-09 2017-03-08 3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas

Country Status (13)

Country Link
US (3) US10954220B2 (lt)
EP (2) EP3884939B1 (lt)
CY (1) CY1124338T1 (lt)
DK (1) DK3426243T3 (lt)
ES (2) ES2883328T3 (lt)
HR (1) HRP20211220T1 (lt)
HU (1) HUE055197T2 (lt)
LT (1) LT3426243T (lt)
PL (2) PL3426243T3 (lt)
PT (1) PT3426243T (lt)
RS (1) RS62271B1 (lt)
SI (1) SI3426243T1 (lt)
WO (1) WO2017156165A1 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014882B2 (en) 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PT3426243T (pt) 2016-03-09 2021-08-19 Raze Therapeutics Inc Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
US11319295B2 (en) 2017-10-09 2022-05-03 Merck Sharp & Dohme Corp. Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4200281A1 (en) * 2020-08-18 2023-06-28 Hutchison Medipharma Limited Pyrimidinone compounds and uses thereof
IL308122A (en) 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
BR0007532A (pt) 1999-01-13 2001-11-20 Univ New York State Res Found Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
DK1235830T3 (da) 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
WO2003035621A1 (en) 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2319894T3 (es) 2002-08-14 2009-05-14 Silence Therapeutics Aktiengesellschaft Uso de la proteina quinasa-n-beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
NZ543897A (en) 2003-05-30 2009-04-30 Gemin X Pharmaceuticals Canada Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CN100577680C (zh) 2003-07-03 2010-01-06 宾夕法尼亚大学理事会 对Syk激酶表达的抑制
DK1761540T3 (en) 2004-05-13 2016-11-21 Icos Corp Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
CA2589773A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2617557A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
CA2623768C (en) 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
DK1951684T3 (en) 2005-11-01 2016-10-24 Targegen Inc BIARYLMETAPYRIMIDIN kinase inhibitors
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060631A1 (es) 2006-04-26 2008-07-02 Piramed Ltd Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
RU2009120882A (ru) 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы
BRPI0808888B8 (pt) 2007-03-12 2021-05-25 Cytopia Res Pty Ltd composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008256937A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
SI2288610T1 (sl) 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
HUE035798T2 (en) * 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
US9096579B2 (en) * 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
UA121386C2 (uk) * 2014-04-04 2020-05-25 Айомет Фарма Лтд Похідні індолу, фармацевтична композиція, яка їх містить, та способи їх застосування
US11014882B2 (en) 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PT3426243T (pt) 2016-03-09 2021-08-19 Raze Therapeutics Inc Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos

Also Published As

Publication number Publication date
EP3426243B1 (en) 2021-05-19
US20230312536A1 (en) 2023-10-05
EP3884939C0 (en) 2023-10-25
US11634412B2 (en) 2023-04-25
CY1124338T1 (el) 2022-07-22
HUE055197T2 (hu) 2021-11-29
EP3884939B1 (en) 2023-10-25
SI3426243T1 (sl) 2021-11-30
PT3426243T (pt) 2021-08-19
PL3884939T3 (pl) 2024-02-26
ES2883328T3 (es) 2021-12-07
EP3884939A1 (en) 2021-09-29
US20230009122A1 (en) 2023-01-12
DK3426243T3 (da) 2021-07-19
EP3426243A1 (en) 2019-01-16
US10954220B2 (en) 2021-03-23
ES2965264T3 (es) 2024-04-11
HRP20211220T1 (hr) 2021-10-29
PL3426243T3 (pl) 2021-10-04
US20190071431A1 (en) 2019-03-07
WO2017156165A1 (en) 2017-09-14
RS62271B1 (sr) 2021-09-30
EP3426243A4 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL271999A (en) TYK2 inhibitors and uses thereof
HK1256997A1 (zh) Tyk2抑制劑及其用途
HK1248690A1 (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
AU2015342774B2 (en) EZH2 inhibitors and uses thereof
EP3160477A4 (en) Prmt5 inhibitors and uses thereof
EP3160466A4 (en) Prmt5 inhibitors and uses thereof
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
EP3177288A4 (en) Prmt5 inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
PT3426243T (pt) Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
IL280863A (en) Ototaxin inhibitors and their uses
EP3426244C0 (en) 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL267238A (en) The paranase inhibitors and their use
IL263949A (en) Complement inhibitors and their uses
HK1250926A1 (zh) 抑制劑及其應用
EP3359151A4 (en) CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
IL251162A0 (en) Monoamine oxidase-B inhibitors and rehabilitation
IL267243A (en) The paranase inhibitors and their use
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
AU2014900775A0 (en) Heparanase inhibitors and uses thereof